|
|
Volumn 484, Issue 7395, 2012, Pages S16-S18
|
|
Drug development: Holding out for reinforcements
a
a
NONE
(United States)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIMALARIAL AGENT;
ARTEMETHER PLUS BENFLUMETOL;
ARTEMISINIC ACID;
ARTEMISININ;
ARTESUNATE PLUS MEFLOQUINE;
CHLOROQUINE;
METHYLENE BLUE;
NITD 609;
OZ 439;
PYRIMETHAMINE PLUS SULFADOXINE;
UNCLASSIFIED DRUG;
COST-BENEFIT ANALYSIS;
DISEASE CONTROL;
DISEASE TREATMENT;
DRUG;
HEALTH RISK;
INDUSTRIAL DEVELOPMENT;
MALARIA;
PHARMACEUTICAL INDUSTRY;
PUBLIC HEALTH;
ARTEMISIA ANNUA;
ARTICLE;
CAMBODIA;
GENETIC VARIABILITY;
GENOME;
HUMAN;
IN VITRO STUDY;
MALARIA;
MOSQUITO;
NON PROFIT ORGANIZATION;
NONHUMAN;
PARASITE CLEARANCE;
PHASE 1 CLINICAL TRIAL (TOPIC);
PHASE 2 CLINICAL TRIAL (TOPIC);
PLASMODIUM (LIFE CYCLE STAGE);
PLASMODIUM FALCIPARUM;
PLASMODIUM VIVAX;
PREVENTIVE MEDICINE;
PRIORITY JOURNAL;
REINFORCEMENT;
SIDE EFFECT;
URINE COLOR;
ANTIMALARIALS;
ARTEMISININS;
ASIA, SOUTHEASTERN;
DRUG DISCOVERY;
DRUG RESISTANCE;
DRUG THERAPY, COMBINATION;
HUMANS;
MALARIA;
PLASMODIUM;
TIME FACTORS;
AFRICA;
|
|
EID: 84860768232
PISSN: 00280836
EISSN: None
Source Type: Journal
DOI: 10.1038/484S16a Document Type: Article |
|
Times cited : (12)
|
|
References (6)
|
